Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial o...(Company's core therapeutic areas in addi...),Health

Date:8/22/2008

Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

About MDP

The Microbicides Development Programme (MDP) is an Afro-European partnership to develop vaginal microbicides for the prevention of HIV transmission. MDP is coordinated jointly by Imperial College, London, and the Clinical Trials Unit of the UK Medical Research Council. Partner institutions in Africa are University Teaching Hospital, Lusaka, Zambia; Medical Research Council Uganda Virus Research Institute, Entebbe; African Medical and Research Foundation and National Institute for Medical Research, Mwanza, Tanzania; the Africa Centre for Health and Population Studies, KwaZulu Natal, South Africa; South African Medical Research Council, Durban; and the Reproductive Health and HIV Research Unit, Department of Obstetrics and Gynaecology, University of Witwatersrand, Johannesburg, South Africa. In Mozambique, there are two new MDP sites at the rural Manhica Health Research Centre and at Mavalane Hospital in the urban capital of Maputo. European partners include the London School of Hygiene and Tropical Medicine, St. George's Hospital, London, and the Universities of York, Southampton and Barcelona. Clinical sites are located in South Africa, Tanzania, Uganda, Zambia and Mozambique.

MDP has built a vigorous multicultural and multidisciplinary research network ready to undertake future work of comparable importance and complexity. Years of working collegially have built cohesiveness, efficiency and mutual trust among the scientists, clinical staff, data managers, and other professionals and support staff comprising this Afro-European and pan-African clinical trial network, as well as sound relationships wit
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
6. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO